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ABSTRACT 
The present work describes a validated reverse phase high performance liquid chromatographic method for estimation of 
Clopidogrel in the drug substances and dosage form. The quantification was carried out using Ultron ES OVM (150*4.6) mm, 5µm 
and mobile phase comprised of Buffer, Acetonitrile and in proportion of 70:30 %v/v. The flow rate was 1.0 ml/min and the eluent 
was monitored at 220 nm. The selected chromatographic conditions were found to effectively quantitate Clopidogrel at retention 
time of about 3.8 min. Linearity were found to be in the range of 11-75 μg/ml. The percentage recoveries of all the drugs were found 
to be 99.3-101.1%. The proposed method was found to be fast, specific, accurate, precise, and reproducible and can be used for 
estimation of the Clopidogrel drugs. 
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INTRODUCTION  
Clopidogrel is a prodrug, the action of which may be 
related to an adenosine diphosphate (ADP) receptor 
on platelet cell membranes. The drug specifically and 
irreversibly inhibits the P2Y subtype of ADP receptor, 
which is important in aggregation of platelets and cross-
linking by the protein fibrin. Absorption and 
Distribution: It is rapidly absorbed after oral 
administration of repeated doses of 75 mg Clopidogrel, 
with peak plasma levels of the main circulating 
metabolite occurring approximately one hour after 
dosing.  Absorption is at least 50% based on urinary 
excretion of Clopidogrel related metabolites.Clopidogrel 
undergoes rapid hydrolysis into its carboxylic acid 
derivative. In plasma and urine, the glucuronide of the 
carboxylic acid derivative is also observed. 
 
MATERIALS AND METHODS  
Reagents and Chemicals:  
Clopidogrel drug sample, acetonitrile solvent of HPLC 
grade, potassium di-hydrogen phosphate, water of HPLC 
grade.  
Instruments and Chromatographic Conditions:  
HPLC system with UV/PDA detector was used for 
method development and validation. The separation 
were achieved on Ultron ES OVM (150*4.6) mm, 5µm 
column. The column was maintained at room 
temperature and the eluent was monitored at 220 nm 
using UV detector. The mixture of Potassium 
dihydrogen phosphate buffer 20mM (pH 4.2): 
Acetonitrile 70:30v/v at a flow rate of 1.0 ml/min was 
used as a mobile phase. The injection volume was 20μl. 
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Preparation of Mobile phase: 
Potassium di-hydrogen phosphate buffer 20 mM (pH 
4.2): Acetonitrile in the ratio of 70:30 v/v. 
Preparation of diluent 
Mixed Methanol and water in ratio of 90:10 (v/v) 
Preparation of standard solution 
Weighed about 75 mg of Clopidogrel standard into 50 
mL volumetric flask. Added 30 mL of diluent, sonicated 
to dissolve and made up volume with diluent and mixed 
well. Further, 5 ml of above solution dilute to 200 ml 
with diluent. 
Preparation of sample solution 
Weighed 20 tablets to find out average weight and 
crushed in to mortal pestle. Weighed the crushed sample 
equivalent to 375 mg of Clopidogrel and transferred in 
to 500 ml of volumetric flask. Added about 400 ml of 
diluent and sonicated for 60 minutes than made up 
volume with diluent and mixed well.  Further, 5 ml of 
above solution dilute to 100 ml with diluent. 
Chromatography parameter: 
Column Ultron ES OVM 
(150*4.6)mm,5µm  
Sample temp. 25°C 
Injection volume 20µL 
Flow rate 1.0ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Diluent BUFFER:ACN (70:30) 
Mobile phase B Acetonitrile 
Mobile phase A BUFFER pH 4.2 
Run time 8 minutes 
 
 
RESULTS AND DISCUSSION 
Typical chromatogram of sample 
 
Validation of RP-HPLC method 
1 System precision 
The % RSD for area response of six replicate injection 
for standard solution found to be 1.5 % which is within 
the acceptance criteria of 2.0% 
No. of Injections Area 
1 2022230 
2 2098623 
3 2104221 
4 2098231 
5 2087221 
6 2105561 
Average 2086014.5 
SD 31911.4 
% RSD 1.5 
 
2 Specificity 
There are no any interference or peak observed from 
blank and placebo chromatogram at the retention time of 
Clopidogrel peak 
3 Method precision 
The % RSD for % assay of six replicate sample 
preparation were found to be 0.5 % which is within the 
acceptance criteria of 2.0% 
No. of preparations % Assay 
1 98.7 
2 99.3 
3 99.1 
4 98.1 
5 99.2 
6 99.5 
Average 99.0 
SD 0.5 
% RSD 0.5 
 
4 Accuracy 
Accuracy were performed on 11 µg/ml (30%), 37.5 
µg/ml (100%) and 75 µg/ml (200%). The mean % 
recovery found to be as below table. 
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Accuracy level Concentration (µg/ml ) % Recovery  % Mean recovery 
30% preparation-1 
11 µg/ml 
99.5 
100.4 30% preparation-2 100.5 
30% preparation-3 101.1 
100% preparation-1 
37.5 µg/ml 
99.3 
99.6 100% preparation-2 99.8 
100% preparation-3 99.6 
200% preparation-1 
75 µg/ml 
100.4 
100.1 200% preparation-2 99.6 
200% preparation-3 100.2 
 
5 Linearity 
Linearity were performed on 5 concentration level considering 11 µg/ml (30%) to 75 µg/ml (200%). The correlation 
coefficient found to be 1.000. 
S.No. Linearity Level Concentration Area response 
1 Linearity at 30% 11.1 604343 
2 Linearity at 50% 18.8 1099112 
3 Linearity at 100% 37.6 2098899 
4 Linearity at 150% 56.3 3124153 
5 Linearity at 200% 75.1 4109856 
Correlation coefficient 1.000 
 
6 Robustness 
Following parameters were changed one by one and 
their effect was observed on system suitability for 
standard preparation.  
1. Flow rate of mobile phase was changed (± 0.2 
ml/min) 0.8 ml/min and 1.2 ml/min. 
2. pH of Mobile phase  was changed ( ± 0.2 )  4.0 & 4.4. 
3. Ratio of Mobile phase was changed (±2) Buffer: 
Acetonitrile (72:28) and Buffer: Acetonitrile (68:32) 
The system suitability parameter was found to be within 
the acceptance criteria in all above conditions. 
CONCLUSION 
From the above discussion it can be concluded that the 
proposed method is specific, precise, accurate, linear 
and robust. Results are in good agreement with label 
claim which indicates there is no interference of 
excipients. Therefore the proposed method can be used 
for routine analysis of Clopidogrel in drug substances 
and formulation.  
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